You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The study showed the test had a high negative predictive value, but critics cited a lack of data on cost and outcomes.
Pro-Lab will shepherd Medicortex's kit through the regulatory processes in Canada and the UK, as well as clinically validate it. It will have exclusive rights to sell the kit in the two nations.
The blood-based test is based on three serum biomarkers —matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1.